Objective To explore the analysis of Montelukast joint Budesonide clinical curative effect and safety for the treatment of infantile asthma.Methods 80 cases of pediatric asthma patients from June 2014 to June 2016 in our hospital were selected as the research object, and randomly divided into observation group and the control group,40 cases in each group, the control group treated with conventional Budesonide therapy,the observation group with the Montelukast with Budesonide therapy, compared to observe the clinical therapeutic effects of two groups of children and its adverse reactions.Results Observation group with clinical total effective rate was 100.00%, which was significantly higher than the control group 82.50%(P<0.05);The time of disappearance of asthma, the disappearance time of cough, wheezing and the disappearance of wet sound were shorter in observation group than in control group (P<0.05); After treatment,After treatment, the observation group PEF, FEV1, FEVI /FVC scores were significantly better than the control group, and observation group Hs-CRP, TNF-α, IL-6, IL-10 indicators improved better than the control group, With statistical significance (P<0.05); But there was no significant difference between the two groups in adverse reaction rate.Conclusion Children with asthma by Montelukast with Budesonide therapy of clinical effect is remarkable, can effectively improve the clinical symptoms, and will not increase adverse reactions, has high clinical application security.%目的 探究孟鲁司特联合布地奈德治疗小儿哮喘的临床疗效及其安全性.方法 随机选取2014年6月~2016年6月台州市椒江区妇幼保健计划生育服务中心收治的80例小儿哮喘患者为研究对象,并将其随机分为观察组和对照组,各40例,其中对照组患儿接受常规布地奈德治疗,观察组患儿采用孟鲁司特联合布地奈德治疗,观察比较2组患儿的临床治疗效果及其不良反应情况.结果 观察组患儿临床治疗总有效率为100.00%,明显高于对照组82.50%(P<0.05);观察组气喘消失时间、咳嗽消失时间、哮鸣音及湿音消失时间均短于对照组(P<0.05);治疗后,观察组PEF、FEV1、FEVI/FVC评分均明显优于对照组,且观察组患儿Hs-CRP、TNF-α、IL-6、IL-10指标改善程度优于对照组,差异均具有统计学意义(P<0.05);2组患儿不良反应率比较差异无统计学意义.结论 小儿哮喘采用孟鲁司特联合布地奈德治疗的临床效果显著,能够有效改善临床症状,且不会增加不良反应,具有较高的临床应用安全性.
展开▼
